Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
UK Biobank generates “largest open access resource of exome data”
It has also better specified new disease-related algorithms in chronic obstructive pulmonary disease, kidney disease, dementia, Parkinson’s disease, heart attack and stroke.
Latest news
-
Q&A: Pernille Laerkegaard Hansen
Our scientific projects are world class and I work with many people within AstraZeneca’s R&D Biotech Unit at the forefront of chronic kidney disease (CKD) research.
-
First-line ovarian approval cements AZ’s Lynparza lead
Also new data on recently approved kidney disease drug. AstraZeneca’s Lynparza has become the first PARP inhibitor to be approved for first-line maintenance therapy in BRCA-mutated ovarian cancer, ... And in another positive development, AZ also
-
China first market to approve AZ’s kidney drug roxadustat
The product in question is FibroGen-partnered roxadustat for anaemia in chronic kidney disease patients on dialysis and, according to an AZ spokesman, “potentially spells a new era where China starts
-
GSK’s says depot HIV injection works over three years
a potential treatment for anaemia associated with chronic kidney disease.
-
NICE says no to AZ and Vifor’s rival hyperkalaemia drugs
Most common in patients with poor kidney function, heart failure or liver disease, hyperkalemia can be fatal, and patients have had few options for treatment until now. ... The companies argue that this exposes patients to cardiovascular disease risk,
More from news
Approximately 17 fully matching, plus 124 partially matching documents found.
Latest Intelligence
-
China: AstraZeneca’s new engine for growth and innovation
FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.
-
The invisible army
Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.
-
Deal Watch December 2016
1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.
-
Business as usual
He also cautioned delegates over 'dual use', describing a situation where ferric citrate was promoted at a kidney disease symposium. ... It was described as being FDA-approved - which it is, but not for the treatment of kidney disease.
-
Deal Watch February 2016
The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards
This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease. ACT on Anemia was one of a ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel
-
Making good practice common practice in rare disease
However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Account Director, Medical Education
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Scientific Director – Medical Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Senior Medical Writer
-
Salary TBC
-
Health Consultant - Brand Comms
-
Competitive Salary
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
Subscribe to our email news alerts
- Fishawack acquires Dudnyk
- GSK’s myeloma drug hits target, prompting rapid filing pledge
- Winners of the HSJ Partnership Awards 2019 unveiled
- 50 questions for delivering an exceptional healthcare brand experience
- Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
- The brand strategy revolution
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
